Treatment of Glioblastoma Using Split Immunity Vaccine

ABC2 CEO Max Wallace: Our split-immunity research investment

Title: Treatment Of Glioblastoma Using the “Split Immunity” Mode of Vaccination
Investigators: Rachel Grossman, Ilan Volovitz, Zvi Ram
Grantee: Tel Aviv Sourasky Medical Center

The brain has a special relationship with the immune system, the body’s natural defense against invaders: the strength of the immune system’s attack on brain invaders is much less than that in the rest of the body.  However, injecting brain tumor cells directly into the body stimulates an immune system attack strong enough to affect even the brain.  In animals, such an attack causes brain tumor regression and even prolongs survival.  Given the remarkable potential of this work for human brain cancer treatment, ABC2 is funding a new clinical trial at the Tel Aviv Sourasky Medical Center that will test this type of therapy in humans.  In a small, safety-focused trial, patients with malignant glioblastoma will receive injections of living or dead cells from their own brain tumors and then be monitored for immune system and brain tumor changes along with disease progression.  If this clinical trial is successful, it could change way malignant glioblastoma is treated and pave the road for future clinical trials maximizing treatment efficacy.